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ABSTRACT Interindividual differences in the response to dietary intake are, in some cases, genotype dependent.
Moreover, genotype-environment interactions may appear when the impact of lifestyle factors (e.g., diet) on a
phenotype (e.g., BMI  30 kg/m2) differs by genotype. A case-control study (obese subjects vs. normal weight
controls) was conducted to assess a possible effect modification on obesity risk of the Gln27Glu polymorphism for
the 2-adrenoceptor gene depending on dietary intake. The sample included 159 subjects with BMI  30 kg/m
2
and 154 controls with BMI  25 kg/m2. The allele frequency for the Glu27 polymorphism, as assessed by the
polymerase chain reaction-restriction fragment length polymorphism methodology, was 0.40 in cases (obese) and
0.37 in controls (lean), which was similar to that of other Caucasian populations. The dietary intake was estimated
by using a previously validated food frequency questionnaire. Obesity incidence was not directly affected by the
polymorphism [odds ratio (OR)  1.40; P  0.246]. However, a significant interaction (effect modification) between
carbohydrate (CHO) intake and the presence of the Glu27 variant in the probability of obesity was apparent. Thus,
females with the polymorphism and a higher CHO intake [49% energy (E)] had a higher obesity risk (OR  2.56,
P  0.051). The product-term introduced in the logistic model to assess effect modification revealed a marginally
significant interaction (P  0.058) between both factors. Furthermore, a high intake of CHO (E  49%) was
associated with higher insulin levels among women carrying the Gln27Glu polymorphism (P  0.01). This
gene-nutrient interaction emphasizes the importance of examining the outcome of some obesity-related mutations
depending on lifestyle (including diet) and may explain the heterogeneity of findings from previous studies. J.
Nutr. 133: 2549–2554, 2003.
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The onset and development of obesity have been associated
with inadequate dietary and sedentary habits, as well as a
genetic predisposition (1,2). The impact of at least 250 genes
or chromosomal regions on body fat variability has been de-
scribed in humans by means of association and linkage studies
as well as through a number of different molecular genetic
approaches (3). Furthermore, evidence from both genetic and
molecular epidemiological studies suggests that genetic factors
are involved in determining the susceptibility to gaining or
losing fat in response to diet or in the higher risk of developing
comorbidities generally observed in obese subjects (4–6).
Most studies concerning gene-diet interactions in humans
have used lipid or lipoprotein phenotypes as the outcome
(7–10), whereas less information is available concerning nu-
tritional influences on gene expression affecting body weight
homeostasis (11,12). Thus, despite the findings that genetic
factors may play an important role in the etiology of obesity
and the increasing number of related genes identified (3),
relatively little is known about the role of genetic traits in the
response of different obesity genotypes to alterations in the
energy balance or diet composition (13,14). Advances in this
field have been delayed by the occurrence of polygenic (gene
 gene) interactions affecting the obese phenotype and by the
influence of environmental factors (gene  environment in-
teractions) such as dietary intake and physical activity (15–
18). In addition to the increasing number of genes apparently
involved in obesity, a major difficulty arises from the fact that
factors such as age, gender and physical activity patterns are
likely to induce effect modifications (19,20), thus hampering
interpretation of the data (21,22). Association studies of gene
variants and assessments of the response to dietary challenges
represent promising ways of investigating gene-nutrient inter-
actions (23).
In this context, the role of a number of genes such as 2-
and 3-adrenoceptors, fatty acid binding protein and peroxi-
some proliferator-activated receptor- (PPAR)2 has been
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2 Abbreviations used: 2-AR, 2-adrenergic receptor gene; CHO, carbohy-
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ascribed to the control of lipid metabolism and to the regula-
tion of body fat variability (3,24). 2-Adrenergic receptors
affect lipolysis, and different 2-adrenergic receptor gene (2-
AR) polymorphisms have been associated with higher BMI
(25), but not in all populations (26,27). Therefore, the aim of
this study was to assess, using a case-control design, whether
the macronutrient distribution of dietary intake may influence
the risk of obesity in individuals carrying the Gln27Glu poly-
morphism of the 2-AR gene.
MATERIALS AND METHODS
Study population. The methods of this study have been previ-
ously reported (19–21). Thus, the surveyed population was recruited
from the Endocrinology and Occupational Health Departments at
the Navarra Hospital between January 1999 and June 2000 and was
comprised of 313 Spanish subjects (66 men), aged 20–60 y (the mean
age for the surveyed population was 41 y). We based the study on
a case-control design, defining cases of obesity as those individuals
having BMI  30 kg/m2. Exclusion criteria were exposure to hor-
monal treatment or development of secondary obesity due to endo-
crine disease or serious intercurrent illness. Subjects with type 2
diabetes who were not receiving glucose-lowering agents were eligible
as cases (9%). Controls were healthy subjects having a BMI  25
kg/m2 with no apparent disease and blood pressure 120/90. In total,
159 obese patients (BMI, 37.7  5.3 kg/m2) and 154 normal-weight
subjects (BMI, 22.0  1.8 kg/m2) were selected. Response rates were
acceptable (65% for cases and 75% for controls), and the interviews
were all conducted in a medical environment with little or no time
pressure. The study was approved by the Ethics Committee of the
University of Navarra, and all subjects provided written informed
consent for participation. All reported investigations were carried out
according to the principles of the Declaration of Helsinki II.
Dietary intake was assessed through a previously validated food
frequency questionnaire for population studies including 136 items
(28), and energy intake and macronutrient distribution were calcu-
lated from values obtained from two reliable Spanish food composi-
tion tables (29,30). Physical activity and time spent sitting during
leisure time were estimated with a previously validated questionnaire
and assessed as metabolic equivalents (MET) (MET  h/wk) or h/wk,
respectively (31). MET represent the ratio of energy expended during
a physical activity to the metabolic rate of sitting quietly, and are
independent of body weight. The number of hours spent participating
in each activity was multiplied by the MET score specific to each
activity, thus obtaining the weekly MET  h.
Procedures. Weight and height were measured by conventional
protocols as described elsewhere (32). Also, following a 12-h fast,
venous blood samples were obtained, and the serum glucose and the
lipid profile were measured by enzymatic methods (33). Serum insulin
was measured by radioimmunoassay (TKIN1 kit; Diagnostic Products,
Madrid, Spain) and plasma leptin by a commercial enzyme immuno-
assay (EIA-1863 kit; DRG Diagnostics, Marburg, Germany). Blood
samples were taken for the extraction and characterization of
genomic DNA from leukocytes as previously described (19–21). The
DNA segment containing codon 27 of the 2AR gene was amplified
by polymerase chain reaction (PCR) carried out in a volume of 30 L
containing 200 ng of genomic DNA, 10 pmol of each primer (up-
stream, 5-CCGCCGTGGGTCCGCC-3, and downstream, 5-
CCATGACCAGATCAGCAC-3), 200 mol/L of deoxynucle-
otide triphosphate, 1.5 mmol/L of magnesium chloride, 3 L of
reaction buffer (10: 160 mmol/L of (NH4)2SO4, 670 mmol/L of
Tris-HCl (pH 8.8 at 25°C) and 0.1% Tween 20) and 0.8 U of Taq
polymerase (BIOTAQ; Bioline, London). The PCR began with de-
naturation at 94°C for 5 min, followed by 35 cycles of denaturation
at 94°C for 30 s, annealing at 65°C for 30 s and extension at 72°C for
30 s, with a final extension at 72°C for 10 min. Ten L of PCR
products (310 bp) were digested with the addition of 10 L of a
mixture containing 6 U of ItaI, a specific restriction enzyme for the
sequence GC/NGC (Roche Diagnostics, Somerville, NJ) and the
reaction buffer. This mixture was incubated at 37°C for 2 h, and the
digested samples were separated by electrophoresis through a 2.5%
agarose gel and visualized by staining with ethidium bromide.
Statistical analyses. A two-way factorial ANOVA (2  2) was
used to assess the association between several anthropometric, di-
etary, metabolic and lifestyle characteristics of the sample and the
presence of obesity (case) and/or the presence of the 2-adrenoceptor
mutation. The significance of the interaction between the presence of
obesity and the presence of the polymorphism was also obtained.
Different equations were modeled using logistic regressions to
analyze the relationship between the macronutrient intake [dichot-
omized at the median of carbohydrate (CHO), lipid and protein
consumption] and the polymorphism on the risk of obesity. All of the
analyses were carried out separately in men and women and were
adjusted for confounding factors such as age and physical activity
during leisure time measured in MET  h/wk.
As we have reported previously (19), significant interactions have
been found for the Glu27 polymorphisms of the 2-AR and physical
activity. Therefore, we conducted stratified analyses for the groups
with or without the 2-adrenergic mutation to facilitate the inter-
pretation of the results.
Because of the presence of a marginally significant interaction
between intake of CHO and the polymorphism among women, we
presented the natural logarithm of the odds ratios (OR) of being
obese according to the intake of CHO [% energy (E)] as a continuous
variable separately in women with and without the polymorphism.
The association between CHO intake (dichotomized at the me-
dian or as quartiles) and the level of insulin was also assessed by
Student’s t test and a linear regression model only in women because
of the small size of the sample of men (n  66). Because the
distribution of the insulin levels presented a positive skewness, its log
transformation as the dependent variable was considered. All of the
statistical analyses were carried out by using the SPSS package
software (version 10.0). Differences with values of P  0.05 were
considered significant, and those with values of P  0.05 and 0.10
were considered marginally significant.
RESULTS
The polymorphism distribution was similar for case and
control subjects, with the Gln27Gln genotype found in 35.8%
of the obese subjects and in 40.2% of the controls, and the
Glu27Glu genotype found in 16.0% of the obese subjects and
14.3% in lean individuals. As expected, all obesity phenotype
characteristics concerning anthropometric (e.g., weight and
BMI) and biochemical markers (e.g., glucose, insulin, leptin
and lipid profile) differed between obese and lean individuals
in this population (Table 1). Data obtained from the food
frequency questionnaire suggested that obese individuals (mu-
tated and nonmutated) underreported dietary energy intake
(8800 kJ/d) compared with lean controls (10,900 kJ/d)
with a trend to report protein overconsumption at the expense
of fat (Fig. 1). The reported CHO intakes did not differ
between groups but were related to the triglyceride levels (P
 0.07), giving some support to the validity of the dietary
assessment we used for this study. In addition to a likely
underreporting, obese individuals declared a lower level of
physical activity (Table 1), which may explain in part the
reduced energy intake in these subjects.
Obesity incidence was not directly affected by the polymor-
phism (OR 1.40, P 0.246). The analysis of the association
between CHO intake and the Glu27 allele on obesity risk was
assessed through a multivariate logistic model. After introduc-
ing in the model the previously reported interaction between
the 2 -adrenergic mutation and physical activity, a marginally
significant interaction between the polymorphism and the
CHO intake was found among women (Table 2). This finding
suggested that a dietary intake higher than the median CHO
consumption (49% E) produced an increased obesity risk in
those women carrying the Glu27 allele (OR  2.56, P
 0.051) when adjusted for age and physical activity. A
second model, using the CHO/fat ratio instead of the percent
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derived from CHO supported these results, because a CHO/fat
intake ratio of 1.77 was associated with a higher risk of
obesity (OR  3.21, P  0.02) in women with the 2-
adrenoceptor gene polymorphism.
The natural logarithms of the OR of being obese for women
with and without the polymorphism according to the intake of
CHO were marginally significant for women with the poly-
morphism (b  0.074, P  0.056), using the lower level of
intake as the reference and adjusted for age and physical
activity (Fig. 2).
Additionally, a relationship between CHO intake and in-
sulin levels (log transformed) among women was found, and
this relationship showed that an intake of CHO above the
median (49% E) was associated with higher insulin levels
(Fig. 3) among women carriers of the polymorphism in the
2-adrenoceptor gene (P  0.01). Moreover, a positive linear
trend (data not shown) for insulin levels was observed across
quartiles of CHO intake within the mutated group (P 0.03).
DISCUSSION
Obesity results from the combined effects of genes, envi-
ronment and lifestyle (1,6). In this context, an understanding
of the interactions between macronutrient intake and the
genotype is important to provide a basis for determining the
role of dietary intake and habits in the prevalence of different
pathological conditions such as obesity (34). The effects of
nutrition on the phenotype can be exerted at many stages
between transcription of the genetic sequence and production
of a functional protein (35).
Although the specific role of the dietary macronutrient
intake in the prevalence of obesity is still controversial
(2,33,36), genotype-environment interactions arise when the
phenotypic response (e.g., fat mass) to lifestyle habits (e.g.,
diet) is modulated by the genotype of the individual (5). It is
well established that individual responses to different dietary
interventions may be genotype dependent (6,37); however,
most studies have ignored the gene-environment interactions
due to the difficulty of examining the role of common poly-
morphisms in the absence of data concerning nongenetic
exposures (14,38).
Some evidence for gene-environment interactions has been
obtained not only by comparing the influence of a gene on a
given phenotype in populations with different dietary habits or
by categorizing on the basis of dietary variables that potentially
affect the phenotype, but also by assessing the response to a
dietary intervention among individuals with different geno-
types at a given candidate gene or marker locus (6). Case-
control approaches therefore provide a unique opportunity to
explore multicausality for a given gene-diet interaction
(39,40) by using a homogenous population with selected cri-
teria of inclusion (BMI  30 kg/m2 for cases and BMI  25
TABLE 1
Anthropometric, metabolic and lifestyle variables, including energy intake and physical activity indicators, in obese (case) and
normal weight (control) subjects stratified by the presence of the Gln27Glu polymorphism1
Cases Controls



















Men, % 7.0 15.7 30.6 23.9
Age, y 40.1  10.4 39.3  9.1 37.5  8.9 42.3  10.6
Current weight, kg 96.2  15.9 95.3  17.0 62.8  10.7 60.6  9.5 0.34  0.01 0.70
Weight at 20 y, kg 69.8  16.6 68.1  16.5 59.7  12.2 57.9  9.6 0.29  0.01 0.95
Maximum weight, kg 100.6  16.0 98.8  17.2 66.7  12.6 64.4  10.6 0.22  0.01 0.89
Body mass index, kg/m2 38.1  5.6 37.3  5.8 22.3  1.9 22.3  1.8 0.42  0.01 0.35
Glucose, mmol/L 103.6  35.6 100.2  20.1 91.7  9.2 93.4  14.4 0.75  0.01 0.30
Total cholesterol, mmol/L 209.5  36.7 208.1  39.6 192.0  29.8 198.0  37.6 0.59  0.01 0.39
Leptin, ug/L 34.5  29.1 34.4  32.4 7.3  6.5 8.3  8.3 0.86  0.01 0.82
Insulin, pmol/L 150.0  162.0 147.6  125.0 57.6  34.8 52.2  28.2 0.74  0.01 0.90
Energy, kJ/d 8907  3243 8722  2681 11444  2807 10536  4714 0.28  0.01 0.47
Sitting (h/wk) 32.2  12.9 28.8  12.9 20.5  8.8 22.1  8.3 0.48  0.01 0.05
Physical activity (MET  h/wk)2 9.3  10.3 10.8  14.8 24.1  21.2 18.3  19.9 0.28  0.01 0.07
1 Values are means  SD.
2 Metabolic equivalents (MET) represent the ratio of energy expended during a physical activity to the resting metabolic rate. The number of hours
spent participating in each activity during a week were multiplied by the MET score specific to each activity, thus obtaining the weekly MET  h.
FIGURE 1 Macronutrient distribution as a percentage of energy
intake (% E) in obese (case) and control individuals with and without the
Gln27Glu polymorphism. Values are means  SD (n  313). Carbohy-
drate (CHO) intake did not differ between case and control subjects
overall (P  0.42). There were no differences between case and control
subjects within genotype for CHO (P  0.73), fat (P  0.38) or protein
(P  0.12) intakes.
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kg/m2 for controls) despite the difficulties that usually arise in
recruiting the study population (31). The association in these
studies is commonly assessed through the OR calculated by
logistic regression analyses to perform multivariate adjust-
ments for confounding factors and to take into account effect
modifiers (39).
A limitation in these kinds of studies is that the tendency
for the obese individuals to underestimate their dietary energy
intake influences the macronutrient distribution pattern, par-
ticularly the dietary protein and lipid values (41,42). There-
fore, we focused only on the CHO intake, because we found no
statistical differences between obese and lean subjects, but an
association between insulin and triglyceride levels was ob-
served, which indirectly supports the validity of the CHO
intake data.
The -adrenoreceptors are involved in adipocyte lipid mo-
bilization (7,43), and a number of genetic polymorphisms
(Gln27Glu, Arg16Glu, Thr164Ile and Val34Met) have been
associated with the risk of obesity (6,44,45) through changes
in the receptor function (7,25,46). The Glu27 allelic fre-
quency of the 2 -adrenoceptor gene polymorphism was high
in both case (0.40) and control (0.37) groups, being in Hardy-
Weinberg equilibrium. This distribution is similar to that of
other European populations (7,47,48), but different from the
Japanese allelic frequency (49). However, not all studies have
demonstrated a significant association between the Gln27Glu
polymorphism and obesity (26,27). These controversial find-
ings could be explained, in some cases, by not having taken
into account potential effect modifiers such as age, gender or
physical activity as well as the dietary pattern (20,21).
Moreover, although the mutation cannot be considered as
the definite cause of obesity, the polymorphism has shown in
some circumstances a different effect in men than in women
(19,50,51). The current analysis revealed that the effect of the
Gln27 mutation on the obesity risk was modified by the
macronutrient composition of the diet, when adjusted by age
and physical activity. That is, a higher CHO intake may
actually increase the obesity risk in women carrying the Glu27
allele, which may be associated not only with a hyperinsuline-
mic response in these subjects but also with changes in the
CHO/fat proportions oxidized as a consequence of an impaired
2-adrenoceptor function. Among female subjects bearing the
Glu27 polymorphism, an association between high CHO in-
take and higher insulin levels (P  0.03) was apparent, which
may contribute to the greater likelihood of an onset of obesity
among these subjects.
The fact that some studies have shown that a polymor-
FIGURE 3 Mean insulin levels according to carbohydrate (CHO)
intake among women (n  247) categorized according the presence of
the Gln27Glu polymorphism (P interaction  0.17). Values are means
 SEM. Means with a different letter differ, P  0.01. E, Energy.
TABLE 2
Association (OR) between carbohydrate intake and obesity (multivariate logistic regression model) categorized by the Gln27Glu
polymorphism adjusted for age and physical activity during leisure time (metabolic equivalents  h/wk)1
Carbohydrate intake (%E)
Gln27Gln genotype Gln27Glu polymorphism
OR 95% CI P OR 95% CI P
Women
49 1 (ref.) 1 (ref.)
49 0.53 (0.15–1.86) 0.32 2.56 (1.00–1.16) 0.051
Interaction (effect modification) 0.058
Men
49 1 (ref.) 1 (ref.)
49 0.13 (0.001–19.42) 0.42 1.39 (0.12–15.55) 0.79
Interaction (effect modification) 0.504
1 Abbreviations used: OR, Odds ratio; E, energy; 95% CI, 95% confidence interval; ref., reference category.
FIGURE 2 Natural logarithms of the odds ratios (LnOR) of being
obese for women with and without the polymorphism (logistic regres-
sion model) according to the intake of carbohydrates (CHO) (% energy)
and adjusting for age and physical activity during leisure time (meta-
bolic equivalents  h/wk).
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phism on the 2-AR adversely reduces fat oxidation (16,48),
which may consequently be associated with hyperlipidemia,
insulin resistance and hyperinsulinemia (52), also helps to
explain that carriers of the Glu27 allele may show an impaired
response after high CHO intake leading to obesity. This sug-
gestion is confirmed not only by the positive association be-
tween a high CHO intake and insulin levels observed in this
case-control study, as assessed by the quartiles of the CHO
intake in Glu27 allele carriers, but also by the marginal cor-
relation between CHO intake and triglyceride levels (53).
Apparently, this is the first time that a gene  diet inter-
action has been described for this gene polymorphism, al-
though a number of studies have reported the influence of
dietary intake on other polymorphisms such as Pro12Ala for
the PPAR locus (14) or different Apo gene variants (8–10) and
for other mutations (54). Furthermore, some examples of the
role of the genotype affecting the weight-loss response to
low-energy diets have been reported in obese women for
uncoupling protein 1 gene (UCP1) (51), leptin receptor gene
or leptin gene (55,56) and conjoint 3-adrenoceptor or UCP
gene polymorphism (57,58). Additionally, it has been shown
that a 3-adrenergic receptor gene polymorphism may affect
the anatomical distribution (subcutaneous vs. visceral) of the
body fat diet-induced loss (59) and predict the outcome of
dietary interventions (60). Moreover, genetic variations of the
2 -adrenergic receptor locus have been associated with inter-
individual differences in the response to overfeeding (61). A
previous finding obtained from this Spanish population
showed that individuals bearing the Gln27Glu polymorphism
are somewhat resistant to weight loss induced by physical
activity and are less able to use fat stores as a source of fuel
after a period of exercise (16).
In any case, the current data should be carefully inter-
preted, because they rely on self-reported dietary data, which
may be influenced by the weight status of the individuals and
by their physical activity patterns. Although the studied gene
polymorphism did not have a direct effect on obesity risk,
heterogeneous responses to different dietary situations (e.g.,
macronutrient distribution and weight-reducing methods)
support the possibility that there are individual differences in
the susceptibility to dietary intake and confirm that gene-diet
interactions may have a role in the onset, prevalence and
dietary management of obesity (62,63).
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